Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
05. Juli 2023 08:45 ET
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
11. Mai 2023 09:05 ET
|
Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...